Treatment of lymphoid and myeloid malignancies by immunomodulatory drugs

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F19%3A00012008" target="_blank" >RIV/00023736:_____/19:00012008 - isvavai.cz</a>
Result on the web
<a href="https://doi.org//10.2174/1871529X18666180522073855" target="_blank" >https://doi.org//10.2174/1871529X18666180522073855</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/1871529X18666180522073855" target="_blank" >10.2174/1871529X18666180522073855</a>

Result language
angličtina
Original language name
Treatment of lymphoid and myeloid malignancies by immunomodulatory drugs
Original language description
Thalidomide and its derivatives (lenalidomide, pomalidomide, avadomide, iberdomide hydrochoride, (CC-885 and CC-90009) form the family of immunomodulatory drugs (IMiDs). Cereblon acts as the substrate receptor of a cullin-4 really interesting new gene (RING) E3 ubiquitin ligase CRL4CRBN. This E3 ubiquitin ligase in the absence of lenalidomide ubiquitinates CRBN itself and the other components of CRL4CRBN complex. Presence of lenalidomide changes specificity of CRL4CRBN which ubiquitinates two transcription factors, IKZF1 (Ikaros) and IKZF3 (Aiolos), and casein kinase 1α (CK1α) and marks them for degradation in proteasomes. Both these transcription factors (IKZF1 and IKZF3) stimulate proliferation of MM cells and inhibit T cells.
Czech name
—
Czech description
—

Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)